法尼基转移酶抑制剂：前景与现实

Farnesyltransferase inhibitors: promises and realities.

作者信息

Cox Adrienne D, Der Channing J

机构信息

Department of Radiation Oncology CB #7512, 1050 Gravely Building, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7512, USA.

出版信息

Curr Opin Pharmacol. 2002 Aug;2(4):388-93. doi: 10.1016/s1471-4892(02)00181-9.

DOI:10.1016/s1471-4892(02)00181-9

PMID:12127871

Abstract

Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias, gliomas and even non-small-cell lung cancers, especially when administered in combination with taxanes. It is possible that the critical target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.

摘要

法尼基转移酶抑制剂最近已显示出对白血病、神经胶质瘤甚至非小细胞肺癌具有临床疗效，尤其是与紫杉烷类药物联合使用时。法尼基转移酶下游负责这些效应的关键靶点可能既不是最常被提及的两种可能性——Ras或RhoB，不过相关研究正在进行中。